🧬 KRAS Cancer Research

KRAS is one of the most frequently mutated oncogenes in human cancer, playing a critical role in the development and progression of several aggressive cancer types, particularly pancreatic, colorectal, and lung cancers. This gene normally acts as a molecular switch controlling cell growth and division, but when mutated, it becomes permanently activated, driving uncontrolled cell proliferation. Understanding KRAS mutations has become increasingly important for cancer researchers and clinicians because these mutations can serve as valuable biomarkers for diagnosis, prognosis, and treatment selection.

The study of KRAS mutations represents a significant area of cancer research innovation. For decades, KRAS was considered "undruggable," but recent breakthrough discoveries have led to the development of targeted therapies specifically designed to inhibit mutated KRAS proteins. These advances are opening new possibilities for patients whose tumors harbor KRAS mutations. Additionally, KRAS testing has become a standard diagnostic tool, helping oncologists identify patients who may benefit from precision medicine approaches and enabling more personalized treatment strategies.

On this page, you'll find comprehensive information about KRAS mutations, their role as cancer biomarkers, the latest diagnostic techniques for detecting KRAS alterations, and current research exploring novel therapeutic approaches. Whether you're a patient, caregiver, or healthcare provider seeking to understand this important oncogene, our curated collection of articles below represents the latest peer-reviewed research findings and clinical developments in KRAS-related cancer research.